Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury

Ann Oncol. 2017 Mar 1;28(3):671-672. doi: 10.1093/annonc/mdw649.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Chemical and Drug Induced Liver Injury / etiology*
  • Cholangitis / chemically induced*
  • Humans
  • Lung Neoplasms / drug therapy
  • Male
  • Nivolumab

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab